Terrorist plot bumps network news coverage of tissue-engineered skin momentarily Print E-mail
By M.E.Garza   
Saturday, 30 October 2010 06:10

Shares of  Regenicin (OTC:WDST) closed up at $1.05 +0.13 (14.75%) after trading as high as $1.10 during Friday's session. Investors exchanged nearly 1.2 million shares of the newly trading micro-cap company which recently secured the license for the new science from the Swiss-based pharmaceutical leader Lonza.  Regenicin is reportedly preparing to advance a ground-breaking engineered skin substitute technology to commercialization with, according to our sources, the full support and backing of the U.S. military.

Investors who tuned in to ABC World News Tonight with Diane Sawyer on Friday Night hoping to catch a glimpse of the new technology were dissapointed to find that unplanned coverage of a new, credible terrorist plot against the United States had bumped many of the news stories producers had lined up for the Friday night broadcast. 

BioMedReports reached out to officials who informed us that the story had "only been bumped temporarily" and we learned for the first time that Regenicin's Chief Executive Officer, Randall McCoy will be featured/interviewed as part of the news piece which will now be re-scheduled to air on the network.  Sources told BioMedReports late Friday evening: "Obviously, we cannot control the media, but we do know the story will air shortly. It could be this weekend, it could be during the week. All we can do is monitor the situation." We will also monitor the airwaves and keep our readers posted as soon as we see or hear anything.


One very important thing that we are also expecting as validation of our research into this quickly developing biotech story and the wide media attention it should receive in the days ahead is an official press release from either Regenicin and/or Lonza about the press conference which we were told will take place on Tuesday, November 9th. When official word about the media event is released, we would anticipate more volume and price action to follow.

In the past, similarly priced companies in the same sector, like StemCells, Inc. (NASDAQ:STEM), have traded as high as $6+ dollars after major news media has focused attention to their technologies.


Disclosure: Long WDST

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus